PIP Search Page

Displaying 601 - 620 of 773

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check	Compliance outcome	Date Published Sort ascending
MHRA-100183-PIP01-21-M01 (update)	AZILSARTAN MEDOXOMIL	Treatment of hypertension	Edarbi Edarbi	Cardiovascular Diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		29/07/2022
MHRA-100175-PIP01-21-M01 (update)	AGOMELATINE	Treatment of major depressive episodes	Valdoxan Valdoxan	Psychiatry	PM: decision on the application for modification of an agreed paediatric investigation plan.	Yes		29/07/2022
MHRA-100166-PIP01-21-M01 (update)	ENTRECTINIB	Treatment of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms).	Rozlytrek Rozlytrek Rozlytrek Rozlytrek Rozlytrek Rozlytrek Rozlytrek Rozlytrek Rozlytrek Rozlytrek Rozlytrek Rozlytrek Rozlytrek Rozlytrek Rozlytrek	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		29/07/2022
MHRA-100170-PIP01-21-M01 (update)	CANAGLIFLOZIN HEMIHYDRATE	Treatment of Type 2 Diabetes Mellitus	Invokana	Endocrinology-Gynaecology-Fertility-metabolism	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		29/07/2022
MHRA-100145-PIP01-21-M01 (update)	BRIGATINIB	Non small cell lung cancer Anaplastic large cell lymphoma Inflammatory myofibroblastic tumours	Alunbrig Alunbrig Alunbrig Alunbrig Alunbrig Alunbrig Alunbrig Alunbrig Alunbrig Alunbrig Alunbrig Alunbrig Alunbrig Alunbrig	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		29/07/2022
MHRA-100123-PIP01-21-M01 (update)	SARILUMAB	Treatment of chronic idiopathic arthritis	Kevzara Kevzara Kevzara Kevzara Kevzara	Immunology -Rheumatology-Transplantation	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		29/07/2022
MHRA-100117-PIP01-21-M01 (update)	ISATUXIMAB	Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue	Sarclisa Sarclisa	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		29/07/2022
MHRA-100143-PIP01-21-M01 (update)	TENOFOVIR ALAFENAMIDE FUMARATE	Treatment of chronic viral hepatitis B	Vemlidy	Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		29/07/2022
MHRA-100129-PIP01-21-M01 (update)	Cipaglucosidase alfa	Treatment of glycogen storage disease Type II (Pompe's disease)	Pombiliti	Endocrinology-Gynaecology-Fertility-metabolism	PM: decision on the application for modification of an agreed paediatric investigation plan.	Yes		29/07/2022
MHRA-100130-PIP01-21-M01 (update)	BUPIVACAINE	Postsurgical analgesia	EXPAREL liposomal EXPAREL EXPAREL EXPAREL EXPAREL EXPAREL EXPAREL	Pain	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		29/07/2022
MHRA-100058-PIP01-21-M01 (update)	romosozumab	Treatment of osteoporosis	EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY EVENITY	Endocrinology-Gynaecology-Fertility-metabolism	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		29/07/2022
MHRA-100046-PIP01-21-M02 (update)	cenobamate	Treatment of epilepsy	Ontozry Ontozry Xcopri	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		29/07/2022
MHRA-100037-PIP01-21-M01 (update)	ponesimod	Treatment of Multiple Sclerosis	Ponvory	Neurology Other: Autoimmune disease/disfunction	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		29/07/2022
MHRA-100448-PIP01-22	RUXOLITINIB PHOSPHATE	Treatment of vitiligo	OPZELURA	Dermatology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		29/07/2022
MHRA-100312-PIP01-21	Ritlectinib	Treatment of alopecia areata		Dermatology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	Yes	Partial Compliance Check Granted	29/07/2022
MHRA-100330-PIP01-21	Autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified with the lentiviral vector IDUA LVV, encoding for the human α-L-iduronidase (IDUA) gene (OTL-203)	Treatment of Mucopolysaccharidosis type I, Hurler syndrome (MPS-IH)		Other: Metabolic disorders	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		29/07/2022
MHRA-100315-PIP01-21	Brensocatib	Treatment of non‐cystic fibrosis bronchiectasis		Pneumology - Allergology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		29/07/2022
MHRA-100316-PIP01-21	latozinemab	Treatment of clinically symptomatic or pre-symptomatic frontotemporal dementia (FTD)		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No		29/07/2022
MHRA-100364-PIP01-21	Respiratory Syncytial Virus (RSV) PreF3 recombinant Fusion protein/AS01	Prevention of lower respiratory tract disease caused by respiratory syncytial virus	Not available at present	Vaccines	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		29/07/2022
MHRA-100304-PIP01-21	rozibafusp alfa	Treatment of systemic lupus erythematosus (SLE)	Not available at present	Immunology -Rheumatology-Transplantation Other: Inflammation-Rheumatology SLE	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		29/07/2022

Download XLSX